ACTRN12621001309875已完成未知
A study to assess the effectiveness of a primary care vs central hub invitation to lung cancer screening for Maori participants aged 55-74 in Auckland and Waitemata District Health Boards
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 504
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Diagnosis
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 55 Years 至 74 Years（—）
- 性别
- All
入选标准
- •Participants will be recorded or self-identified as Maori in their primary care enrolment register,
- •Aged between 55 to 74,
- •Enrolled in participating general practices in Auckland or Waitemata District Health Boards
- •Are able to provide informed consent and able to agree to participate.
排除标准
- •Never smokers,
- •Those with clinical symptoms suspicious for lung cancer,
- •Those with a previous diagnosis of lung cancer,
- •People who have received chemotherapy or cytotoxic drugs within the last six months,
研究者
相似试验
招募中
不适用
Preliminary study on evaluating the effectiveness of outpatient Morita therapy for agoraphobiaagoraphobiaJPRN-UMIN000042870Department of Neuropsychiatry, Keio University School of Medicine10
进行中（未招募）
1 期
Efficacy and safety of niraparib in combination with cabozantinib in patients with advanced urothelial cancer.EUCTR2017-004367-12-ESFundación CRIS de investigación para vencer el cáncer71
进行中（未招募）
1 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10029261Term: Neuroblastoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005617-14-DKovartis Pharma AG230
进行中（未招募）
1 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)EUCTR2021-005617-14-CZovartis Pharma AG230
进行中（未招募）
1 期
Study to assess safety and identify dose of ribociclib in combination of temozolomide and topotecan (TOTEM) in patients (12 months – 21 years old) with relapsed or refractory solid tumors (Phase I), and further assess efficacy and safety in patients (12 months – 21 years old) with relapsed or refractory neuroblastoma (Phase II)relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma) in patients from 12 months to 21 years oldEUCTR2021-005617-14-DEovartis Pharma AG230